Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Monte Rosa Therapeutics (GLUE) Income from Continuing Operations (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Income from Continuing Operations data on record, last reported at 27081000.0 in Q3 2025.

  • For Q3 2025, Income from Continuing Operations fell 13.5% year-over-year to 27081000.0; the TTM value through Sep 2025 reached 20940000.0, up 117.54%, while the annual FY2024 figure was 72700000.0, 46.29% up from the prior year.
  • Income from Continuing Operations reached 27081000.0 in Q3 2025 per GLUE's latest filing, down from 12317000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 46907000.0 in Q1 2025 and bottomed at 35178000.0 in Q2 2023.
  • Average Income from Continuing Operations over 3 years is 18231727.27, with a median of 30293000.0 recorded in 2024.
  • The widest YoY moves for Income from Continuing Operations: up 246.65% in 2025, down 13.5% in 2025.
  • A 3-year view of Income from Continuing Operations shows it stood at 33252000.0 in 2023, then skyrocketed by 140.39% to 13431000.0 in 2024, then plummeted by 301.63% to 27081000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 27081000.0 in Q3 2025, 12317000.0 in Q2 2025, and 46907000.0 in Q1 2025.